stockrow
Friday 6 November 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
26.82
1.03
+3.99%
Follow VKTX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
9.33 | 5.72 | 4.72 | 7.27 |
Net Debt/EBITDA |
4.24 | 3.65 | 3.76 | 3.78 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 25.65% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.43 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.54 | 0.72 | 0.98 | 0.75 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | — | (2,126.27) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.76) | (0.99) | (1.08) | (1.17) | |
Cash per Share |
6.26 | 5.22 | 4.31 | 8.13 | |
Shareholders Equity per Share |
5.67 | 4.34 | 3.51 | 4.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.67 | 4.34 | 3.51 | 4.99 | |
Free Cash Flow |
(85.29) | (113.98) | (125.17) | (138.19) | |
Working Capital |
638.93 | 501.88 | 407.91 | 839.10 | |
Net Current Asset Value |
638.93 | 501.88 | 403.98 | 584.43 | |
| Other line items | |||||
Quick Ratio |
9.21 | 5.67 | 4.57 | 7.17 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.76) | (0.99) | (1.08) | (1.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
31.53 | 37.44 | 37.25 | 43.27 | |
Average Assets |
812.03 | 737.62 | 674.87 | 858.29 | |
Average Common Equity |
759.67 | 674.42 | 601.89 | 650.82 |
Columns are period end dates · fundamentals updated 2 Nov 2026